TANAFFOS (Respiration)

TANAFFOS (Respiration)

Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients

Document Type : Review Article

Authors
Seyed Mohammadreza Hashemian 1
Navid Shafigh 2
Golnaz Afzal 3
Hamidreza Jamaati 1
Esmaeil Mortaz 4
Payam Tabarsi 4
Majid Marjani 4
Majid Malekmohammad 5
Farzaneh Dastan 1, 3
Seyed Mehdi Mortazavi 6
Makan Sadr 7
Esmaeil Idani 1
Batoul Khoundabi 8
Abdolreza Mohamadnia 1
Atefeh Abedini 1
Arda Kiani 1
Afshin Moniri 7
Seyed Alireza Nadji 7
Fatemeh Yassari 1
Mojtaba Mokhber Dezfuli 9
Mohammad Varahram 10
Faezeh Eshaghi 1
Mahdi Malekpour 11
Aliakbar Velayati 1
1 Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Anesthesiology and Critical Care Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Tracheal Diseases Research Center (TDRC), NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Department of Nursing, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Virology Research Center (VRC), NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8 Iran-Helal Institute of Applied-Science and Technology, Research Center for Health Management in Mass Gathering, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran
9 Lung Transplantation Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10 Mycobacteriology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
11 Geisinger Medical Center, Danville, PA , USA
Abstract
Background: Inflammatory mediators are an important component in the pathophysiology of the coronavirus disease 2019 (COVID-19). This study aimed to assess the effects of reducing inflammatory mediators using hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the mortality of patients with COVID-19.
Materials and Methods: Twelve patients with confirmed diagnosis of COVID-19 were included. All patients had acute respiratory distress syndrome (ARDS). Patients were divided into three groups, namely, HP, CRRT and HP+CRRT. The primary outcome was mortality and the secondary outcomes were oxygenation and reduction in inflammatory mediators at the end of the study.
Results: Patients were not different at baseline in demographics, inflammatory cytokine levels, and the level of acute phase reactants. Half of the patients (3 out of 6) in the HP+CRRT group survived along with the survival of one patient (1 out of 2) in the HP group. All four patients in the CRRT group died. Serum creatinine (SCr), Interleukin-1 (IL1), Interleukin-6 (IL6), Interleukin-8 (IL8), partial pressure of oxygen (PaO2), O2 saturation (O2 sat), and hemodynamic parameters improved over time in HP+CRRT and CRRT groups, but no significant difference was observed in the HP group (All Ps > 0.05).
Conclusion: Combined HP and CRRT demonstrated the best result in terms of mortality, reduction of inflammatory mediators and oxygenation. Further investigations are needed to explore the role of HP+CRRT in COVID-19 patients.
Keywords
Coronavirus disease 2019
COVID-19
Acute respiratory distress syndrome
ARDS
Inflammatory marker
Hemoperfusion
Continuous renal replacement therapy
Cytokine
Oxygenation
Mortality
TANAFFOS (Respiration)
Volume 19, Issue 4
Autumn 2020
Pages 291-299